BioSpace News Archive

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced preliminary unaudited financial results for the third quarter ended September 30, 2023 and business updates.

BD, a leading global medical technology company, announced that it will report its fiscal 2023 fourth quarter and full year financial results on Thursday, November 9, 2023.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy – Methods & Clinical Development, demonstrating the efficacy of its TALEN-mediated gene correction of mutated PIK3CD gene in APDS1 T-cells.

Bexion Pharmaceuticals, Inc. announced today that the Company will participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum.

Genevant Sciences today announced the use of its LNP technology in Gritstone bio’s (Nasdaq: GRTS) self-amplifying mRNA (samRNA) vaccine candidate against COVID-19 in its CORAL program.

Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, announces significant senior executive hires to further expand services for Novotech’s global biotech clients.

Cassava Sciences, Inc., a clinical-stage biotechnology company focused on Alzheimer’s disease, issued the following statement regarding an internal report purportedly prepared by City University of New York.

Virion Therapeutics, LLC, and Ocean Biomedical, Inc. today announced they have entered into a joint venture to accelerate and expand Virion’s clinical-stage program and pipeline, with the goal of finding cures for patients with cancer and chronic infectious diseases.

OmniAb, Inc. (Nasdaq: OABI) today announced it will hold a virtual Research & Technology event on Thursday, November 9 beginning at 11:00 a.m. Eastern time.

Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program.